Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
Sézary syndrome
adverse events
mogamulizumab
mycosis fungoides
Journal
Clinical journal of oncology nursing
ISSN: 1538-067X
Titre abrégé: Clin J Oncol Nurs
Pays: United States
ID NLM: 9705336
Informations de publication
Date de publication:
01 08 2019
01 08 2019
Historique:
entrez:
20
7
2019
pubmed:
20
7
2019
medline:
22
8
2020
Statut:
ppublish
Résumé
Cutaneous T-cell lymphoma (CTCL), including subtypes mycosis fungoides (MF) and Sézary syndrome (SS), represents a rare group of non-Hodgkin lymphomas. Mogamulizumab is a first-in-class monoclonal antibody that selectively binds to C-C chemokine receptor 4, which is overexpressed on the surface of tumor cells in T-cell malignancies, including MF/SS-type CTCL. This review identifies common diagnostic features of MF/SS, the efficacy and side effect profile of mogamulizumab, and practical management strategies for optimizing the nursing care of patients with MF/SS-type CTCL. Case studies are used to describe the role of mogamulizumab in CTCL and to review practical considerations when administering mogamulizumab to patients. Mogamulizumab is an effective treatment for adult patients with relapsed or refractory MF/SS-type CTCL who have received at least one prior systemic therapy. Infusion reactions and drug eruptions require prompt diagnosis and treatment.
Sections du résumé
BACKGROUND
Cutaneous T-cell lymphoma (CTCL), including subtypes mycosis fungoides (MF) and Sézary syndrome (SS), represents a rare group of non-Hodgkin lymphomas. Mogamulizumab is a first-in-class monoclonal antibody that selectively binds to C-C chemokine receptor 4, which is overexpressed on the surface of tumor cells in T-cell malignancies, including MF/SS-type CTCL.
OBJECTIVES
This review identifies common diagnostic features of MF/SS, the efficacy and side effect profile of mogamulizumab, and practical management strategies for optimizing the nursing care of patients with MF/SS-type CTCL.
METHODS
Case studies are used to describe the role of mogamulizumab in CTCL and to review practical considerations when administering mogamulizumab to patients.
FINDINGS
Mogamulizumab is an effective treatment for adult patients with relapsed or refractory MF/SS-type CTCL who have received at least one prior systemic therapy. Infusion reactions and drug eruptions require prompt diagnosis and treatment.
Identifiants
pubmed: 31322628
doi: 10.1188/19.CJON.E73-E80
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
CCR4 protein, human
0
Receptors, CCR4
0
mogamulizumab
YI437801BE
Types de publication
Journal Article
Review
Langues
eng